DIADEXUS TO USE AGILENT TECHS' DNA MICROARRAYS TO FURTHER CANCER RESEARCH.Agilent Technologies This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. Inc. (NYSE NYSE See: New York Stock Exchange :A), a leading provider of innovative technologies for communications and life sciences, has announced that it has entered into a TAP(1) agreement with diaDexus Inc. for gene expression system technology. This agreement will allow diaDexus to obtain access to Agilent's customizable microarray See micro array. microarray - A technique for performing many DNA experiments in parallel. Nothing to do with computers. technology for research into the molecular basis for cancer and other diseases. Financial details of the agreement were not disclosed. "There is a growing demand for customizable arrays to use in high-throughput High-throughput may refer to:
"Agilent's arrays will allow us to screen thousands of genes that are potentially involved in various cancers. Agilent will print tailored arrays that will power our efforts in the discovery and validation See validate. validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. of novel biomarkers," said Mohan Iyer, vice president of diaDexus' R&D Operations and Business Development. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion